Tau Platelets Correlate with Regional Brain Atrophy in Patients with Alzheimer's Disease.

BACKGROUND Intracellular neurofibrillary tangles are part of the core pathology of Alzheimer's disease (AD), which are mainly composed of hyperphosphorylated tau protein. OBJECTIVES The purpose of this study is to determine whether high molecular weight (HMW) or low molecular weight (LMW) tau protein levels, as well as the ratio HMW/LMW, present in platelets correlates with brain magnetic resonance imaging (MRI) structural changes in normal and cognitively impaired subjects. METHODS We examined 53 AD patients and 37 cognitively normal subjects recruited from two Memory Clinics at the Universidad de Chile. Tau levels in platelets were determined by immunoreactivity and the MRI scans were analyzed using voxel-based morphometry in 41 AD patients. RESULTS The HMW/LMW tau ratio was statistically different between controls and AD patients, and no associations were noted between HMW or LMW tau and MRI structures. In a multivariate analysis controlled for age and education level, the HMW/LMW tau ratio was associated with reduced volume in the left medial and right anterior cingulate gyri, right cerebellum, right thalamus (pulvinar), left frontal cortex, and right parahippocampal region. CONCLUSIONS This exploratory study showed that HMW/LMW tau ratio is significantly higher in AD patients than control subjects, and that it is associated with specific brain regions atrophy. Determination of peripheral markers of AD pathology can help understanding the pathophysiology of neurodegeneration in AD.

[1]  R. Kalaria,et al.  Platelet Tau Protein as a Potential Peripheral Biomarker in Alzheimer's Disease: An Explorative Study. , 2018, Current Alzheimer research.

[2]  Xintao Hu,et al.  Network-selective vulnerability of the human cerebellum to Alzheimer's disease and frontotemporal dementia. , 2016, Brain : a journal of neurology.

[3]  Jorge Sepulcre,et al.  Tau positron emission tomographic imaging in aging and early Alzheimer disease , 2016, Annals of neurology.

[4]  Ya-Fang Chen,et al.  Plasma tau as a window to the brain—negative associations with brain volume and memory function in mild cognitive impairment and early alzheimer's disease , 2014, Human brain mapping.

[5]  D. Ryglewicz,et al.  Correlations between cerebellar and brain volumes, cognitive impairments, ApoE levels, and APOE genotypes in patients with AD and MCI. , 2013, Current Alzheimer research.

[6]  Frederik Barkhof,et al.  Different patterns of gray matter atrophy in early- and late-onset Alzheimer’s disease , 2013, Neurobiology of Aging.

[7]  Henrik Zetterberg,et al.  Plasma tau levels in Alzheimer's disease , 2013, Alzheimer's Research & Therapy.

[8]  Andrea Slachevsky Ch,et al.  [Psychometric properties and diagnostic usefulness of the Addenbrooke's Cognitive Examination-Revised in a Chilean elderly sample]. , 2012, Revista medica de Chile.

[9]  Olivier Colliot,et al.  CSF tau markers are correlated with hippocampal volume in Alzheimer's disease , 2012, Neurobiology of Aging.

[10]  J. Schneider,et al.  National Institute on Aging–Alzheimer's Association guidelines for the neuropathologic assessment of Alzheimer's disease , 2012, Alzheimer's & Dementia.

[11]  Dominic Holland,et al.  Amyloid‐β associated volume loss occurs only in the presence of phospho‐tau , 2011, Annals of neurology.

[12]  H. Soininen,et al.  Plasma Aβ42 and Aβ40 as markers of cognitive change in follow-up: a prospective, longitudinal, population-based cohort study , 2010, Journal of Neurology, Neurosurgery & Psychiatry.

[13]  Nick C Fox,et al.  The clinical use of structural MRI in Alzheimer disease , 2010, Nature Reviews Neurology.

[14]  Ulrich Seidl,et al.  The cerebellum in mild cognitive impairment and Alzheimer's disease - a structural MRI study. , 2008, Journal of psychiatric research.

[15]  K. Ashe,et al.  Accumulation of Pathological Tau Species and Memory Loss in a Conditional Model of Tauopathy , 2007, The Journal of Neuroscience.

[16]  A. Hofman,et al.  Plasma Aβ1–40 and Aβ1–42 and the risk of dementia: a prospective case-cohort study , 2006, The Lancet Neurology.

[17]  S. Maeda,et al.  Increased levels of granular tau oligomers: An early sign of brain aging and Alzheimer's disease , 2006, Neuroscience Research.

[18]  R. Maccioni,et al.  Anomalously phosphorylated tau and Aβ fragments in the CSF correlates with cognitive impairment in MCI subjects , 2006, Neurobiology of Aging.

[19]  F. Rothhammer,et al.  ApoE alleles and tau markers in patients with different levels of cognitive impairment. , 2005, Archives of medical research.

[20]  J. Cummings,et al.  The Montreal Cognitive Assessment, MoCA: A Brief Screening Tool For Mild Cognitive Impairment , 2005, Journal of the American Geriatrics Society.

[21]  W. Klunk,et al.  Imaging brain amyloid in Alzheimer's disease with Pittsburgh Compound‐B , 2004, Annals of neurology.

[22]  J. Morrison,et al.  Progressive degeneration of nonphosphorylated neurofilament protein‐enriched pyramidal neurons predicts cognitive impairment in Alzheimer's disease: Stereologic analysis of prefrontal cortex area 9 , 2003, The Journal of comparative neurology.

[23]  H. Braak,et al.  Phases of Aβ-deposition in the human brain and its relevance for the development of AD , 2002, Neurology.

[24]  Karl J. Friston,et al.  A Voxel-Based Morphometric Study of Ageing in 465 Normal Adult Human Brains , 2001, NeuroImage.

[25]  I Litvan,et al.  The FAB: A frontal assessment battery at bedside , 2000, Neurology.

[26]  K Ball,et al.  Visual attention impairments in Alzheimer’s disease , 2000, Neurology.

[27]  H. Wiśniewski,et al.  Plasma amyloid β‐peptide 1–42 and incipient Alzheimer's disease , 1999 .

[28]  K. Davis,et al.  Neurofibrillary tangles in nondemented elderly subjects and mild Alzheimer disease. , 1999, Archives of neurology.

[29]  C. Jack,et al.  Prediction of AD with MRI-based hippocampal volume in mild cognitive impairment , 1999, Neurology.

[30]  A. Toga,et al.  Cortical variability and asymmetry in normal aging and Alzheimer's disease. , 1998, Cerebral cortex.

[31]  J. Kaye,et al.  High cerebrospinal fluid tau and low amyloid beta42 levels in the clinical diagnosis of Alzheimer disease and relation to apolipoprotein E genotype. , 1998, Archives of neurology.

[32]  J. Nunez,et al.  Diversity of High‐Molecular‐Weight τ Proteins in Different Regions of the Nervous System , 1994, Journal of neurochemistry.

[33]  J. Nunez,et al.  High and Low Molecular Weight r Proteins Are Differentially Expressed from a Single Gene , 1993, Journal of neurochemistry.

[34]  R. Liem,et al.  Expression of high molecular weight tau in the central and peripheral nervous systems. , 1993, Journal of cell science.

[35]  R. Liem,et al.  Primary structure of high molecular weight tau present in the peripheral nervous system. , 1992, Proceedings of the National Academy of Sciences of the United States of America.

[36]  D. Grossi,et al.  Mamillary bodies in Alzheimer's disease , 1989, Acta neurologica Scandinavica.

[37]  M. Kirschner,et al.  Regulation of microtubule protein levels during cellular morphogenesis in nerve growth factor-treated PC12 cells , 1988, The Journal of cell biology.

[38]  H. Buschke,et al.  Impaired ranking of semantic attributes in dementia , 1985, Brain and Language.

[39]  M. Folstein,et al.  Clinical diagnosis of Alzheimer's disease , 1984, Neurology.

[40]  C. P. Hughes,et al.  A New Clinical Scale for the Staging of Dementia , 1982, British Journal of Psychiatry.

[41]  H. Nelson A Modified Card Sorting Test Sensitive to Frontal Lobe Defects , 1976, Cortex.

[42]  S. Folstein,et al.  “Mini-mental state”: A practical method for grading the cognitive state of patients for the clinician , 1975 .

[43]  R. Reitan Validity of the Trail Making Test as an Indicator of Organic Brain Damage , 1958 .

[44]  D. Lahiri Editorial [Progress of “Current Alzheimer Research” and Future Direction] , 2013 .

[45]  A. Slachevsky,et al.  Supplementary Material for: The Technology – Activities of Daily Living Questionnaire: A Version with a Technology-Related Subscale , 2012 .

[46]  A. Slachevsky,et al.  Platelet tau pattern correlates with cognitive status in Alzheimer's disease. , 2012, Journal of Alzheimer's disease : JAD.

[47]  A. Slachevsky,et al.  Human platelets tau: a potential peripheral marker for Alzheimer's disease. , 2011, Journal of Alzheimer's disease : JAD.

[48]        Global prevalence of dementia: a Delphi consensus study , 2006 .

[49]  H. Braak,et al.  Neuropathological stageing of Alzheimer-related changes , 2004, Acta Neuropathologica.

[50]  Karl J. Friston,et al.  COMMENTS AND CONTROVERSIES Why Voxel-Based Morphometry Should Be Used , 2001 .

[51]  S A Small,et al.  Plasma amyloid beta-peptide 1-42 and incipient Alzheimer's disease. , 1999, Annals of neurology.

[52]  M. Schlossberg The Assessment of Aphasia and Related Disorders. 2nd ed. , 1984 .

[53]  A. Rey L'examen psychologique dans les cas d'encéphalopathie traumatique. (Les problems.). , 1941 .